Industry Research Reports

The global market for Spatial Biology was valued at US$ 484 million in the year 2023 and is projected to reach a revised size of US$ 1015 million by 2030, growing at a CAGR of 11.7% during the forecast period.

Valued at US$ 522 million in 2024, the global Spatial Biology market is forecast to reach US$ 1015 million by 2030, at a CAGR of 11.7% during the forecast period.

The global Spatial Biology revenue was US$ 484 million in 2023 and is forecast to a readjusted size of US$ 1015 million by 2030 with a CAGR of 11.7% during the review period (2024-2030).

The global market for Spatial Biology was estimated to be worth US$ 484 million in 2023 and is forecast to a readjusted size of US$ 1015 million by 2030 with a CAGR of 11.7% during the forecast period 2024-2030.

Vaccinia virus (VACV or VV) is the most widely used viral vector for the study of exogenous gene expression and immunogenicity of the resulting protein. Replication-competent recombinant VACV-based vaccines have received increasing attention as potential vaccine vectors for many infectious diseases, as they may be able to elicit potent humoral and cell-mediated immune responses and long-lasting protection.Vaccinia virus (VACV) is a large enveloped, double-stranded DNA virus in the genus of Orthopoxvirus of the family Poxviridae. The VACV genome is comprised of approximately 190,000 nucleotides which encodes approximately 250 genes. VACV is one of the most commonly developed oncolytic vectors. There are several features make VACV a promising oncolytic vector which include excellent lytic activity, natural and broad tumor tropism as well as well-known and easy-manipulating genome structure etc.

Mesenchymal stem cell (MSCs) therapeutic product CDMO (Contract Development and Manufacturing Organization) services refer to a series of services from research and development to production for mesenchymal stem cell-related therapeutic products. CDMOs usually provide outsourcing services to pharmaceutical and biotechnology companies to help them develop and produce biologics in the preclinical and clinical stages.

Mesenchymal stem cell (MSCs) therapeutic product CDMO (Contract Development and Manufacturing Organization) services refer to a series of services from research and development to production for mesenchymal stem cell-related therapeutic products. CDMOs usually provide outsourcing services to pharmaceutical and biotechnology companies to help them develop and produce biologics in the preclinical and clinical stages.

Mesenchymal stem cell (MSCs) therapeutic product CDMO (Contract Development and Manufacturing Organization) services refer to a series of services from research and development to production for mesenchymal stem cell-related therapeutic products. CDMOs usually provide outsourcing services to pharmaceutical and biotechnology companies to help them develop and produce biologics in the preclinical and clinical stages.

Vaccinia virus (VACV or VV) is the most widely used viral vector for the study of exogenous gene expression and immunogenicity of the resulting protein. Replication-competent recombinant VACV-based vaccines have received increasing attention as potential vaccine vectors for many infectious diseases, as they may be able to elicit potent humoral and cell-mediated immune responses and long-lasting protection.Vaccinia virus (VACV) is a large enveloped, double-stranded DNA virus in the genus of Orthopoxvirus of the family Poxviridae. The VACV genome is comprised of approximately 190,000 nucleotides which encodes approximately 250 genes. VACV is one of the most commonly developed oncolytic vectors. There are several features make VACV a promising oncolytic vector which include excellent lytic activity, natural and broad tumor tropism as well as well-known and easy-manipulating genome structure etc.

Mesenchymal stem cell (MSCs) therapeutic product CDMO (Contract Development and Manufacturing Organization) services refer to a series of services from research and development to production for mesenchymal stem cell-related therapeutic products. CDMOs usually provide outsourcing services to pharmaceutical and biotechnology companies to help them develop and produce biologics in the preclinical and clinical stages.